X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Lead Product(s): Exenatide
Therapeutic Area: Nutrition and Weight Loss Product Name: NPM-115
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: NPM-119
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Second Sight Medical Products
Deal Size: Undisclosed Upfront Cash: $55.0 million
Deal Type: Merger August 30, 2022
Details:
Nano Precision Medical, leveraging its proprietary NanoPortalTM drug implant technology, is creating a portfolio of new drugs including NPM’s lead program, NPM-119, that address medication non-adherence, a leading reason for poor clinical outcomes.
Lead Product(s): Exenatide
Therapeutic Area: Endocrinology Product Name: NPM-119
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Nano Precision Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
